Friday, 17 Nov 2017

You are here

Low-dose Bactrim Safe with Methotrexate in AAV

A high proportion of GPA patients receive pneumocystis prophylaxis, usually with TMP-SMX (Bactrim), and drug interactions are always a concern.  

Given that many GPA patients are treated with methotrexate, we often wonder – can my patient safely receive TMP-SMX prophylaxis in conjunction with methotrexate? This concern exists because both methotrexate and TMP work by inhibiting dihydrofolate reductatse and thus it is not surprising that potential for bone marrow toxicity exists. Dr. Tamaki (Japan) presented an abstract this morning looking at safety of low dose TMP-SMX (160mg-800 mg 3x/week or 80mg-400mg/day) when given with methotrexate in patients with AAV.

They performed a retrospective chart review at the Cleveland Clinic (2002-2017) and compared variables between patients receiving methotrexate both with and without TMP-SMX and found the rates of methotrexate discontinuation to be similar between both groups with no differences in reasons for discontinuation (side effect, infection, switching to another medication to treat AAV, methotrexate withdrawal after sustained remission, patient discontinued). Side effects occurred in 8.6% of the methotrexate only group and 7.1% of the methotrexate + TMP-SMX group.

This Cleveland Clinic experience reassures us that it seems safe to administer methotrexate with low dose TMP-SMX, although close monitoring of these patients is key.  

 

Add new comment

More Like This

J&J Hit with a $247 Million Verdict over Metal-on-Metal Hip Replacements

Reuters reports that a federal jury has ordered Johnson & Johnson and its DePuy Orthopaedics division to pay $247 million settlment to six patients who suffered from its defective Pinnacle, metal-on-metal, hip implants. in the US. J&J says it will  appeal this decision.

These implants were associated with tissue necrosis, bone erosion and other injuries due to implant design.

Thiopurines and Anti-TNF drugs in IBD Associated with Increased Lymphoma Risk

JAMA presents a French report on the cancer risk of thiopurine or tumor necrosis factor inhibitor (TNFi) use in adult patients with inflammatory bowel disease (IBD) and finds a raised risk for lymphoma in IBD compared to those not treated with these agents.  (Citation source https://buff.ly/2z04f9h)

Cardiovascular Events: Allopurinol vs. Febuxostat

In the registration trials for febuxostat there were concerns about a cardiovascular (CV) safety signal. In studies of the effect of allopurinol on CV risk/events allopurinol has found to be protective so whether febuxostat is different is a point to clarify.

NSAID and Opioid Adverse Event Reports from MedWatch

One-third of adults in the USA experience chronic pain and take prescription nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, or opioids. This report from the MedWatch system shows that 20% of reports were associated with death, with near equal contribution by NSAIDs, opioids and combination (NSAIDs plus opioids).

CRIB Study Shows No Transplacental Transfer of Certolizumab

Mariette and colleagues have reported on the prospective pharmacokinetic study of placental transfer of certolizumab pegol (CZP) from pregnant women to their infants at the time of birith. They found no to minimal CZP in infant blood at the time of delivery, suggesting a lack of in utero fetal exposure during the third trimester.